Structure Therapeutics reported on August 6, 2026 that the first patients have been dosed in ACCOMPLISH, the phase 3 program for aleniglipron (formerly GSBR-1290), a once-daily oral non-peptide small-molecule GLP-1 receptor agonist for chronic weight management. Like orforglipron, aleniglipron is a small molecule rather than a peptide, so it does not carry the food-and-water timing restrictions of the oral semaglutide (Wegovy) pill and is more straightforward to manufacture at scale.
The program has two randomized, double-blind, placebo-controlled trials. ACCOMPLISH-1 enrolls up to 3,600 adults with obesity, or overweight with a weight-related comorbidity; ACCOMPLISH-2 enrolls up to 1,100 adults with obesity or overweight and type 2 diabetes. Both compare three maintenance doses — 45 mg, 90 mg and 180 mg — against placebo, with participants starting at 2.5 mg and titrating upward in four-week steps. The company said the design follows end-of-phase-2 feedback from the FDA and is intended to support global regulatory submissions.
The move follows the phase 2b ACCESS trial. In the 36-week core study, aleniglipron produced a placebo-adjusted mean weight reduction of up to 11.3% (about 27 lb) at the top dose tested, with weight loss continuing to roughly 16.2% at 44 weeks in an open-label extension. The overall discontinuation rate was 10.4%, and the most common adverse events were gastrointestinal — nausea, vomiting and constipation — consistent with the GLP-1 class. Full phase 2b results were published in Nature Medicine.
Aleniglipron remains investigational; a phase 3 start is the beginning, not the end, of pivotal testing, and reported weight-loss figures come from mid-stage trials that are generally smaller and shorter than the phase 3 studies now under way. Cross-trial comparisons with approved or filed agents (orforglipron, oral and injectable semaglutide, tirzepatide) are unreliable because populations, doses and durations differ.
The broader significance is that oral GLP-1 options are multiplying. Orforglipron was approved in the United States in April 2026 and oral semaglutide in December 2025; aleniglipron and Viking Therapeutics' oral VK2735 are the next small-molecule and dual-agonist candidates moving into or through phase 3. If the ACCOMPLISH results hold, aleniglipron would give prescribers another pill-based option in a field that until recently was dominated by weekly injections.